Publications by authors named "Ian E Krop"

90Publications

Reply to T.J.A. Dekker.

J Clin Oncol 2020 Oct 13;38(28):3351-3352. Epub 2020 Jul 13.

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Haeseong Park, MD, MPH, Washington University School of Medicine, St Louis, MO; Rashmi K. Murthy, MD, MBE, University of Texas MD Anderson Cancer Center, Houston, TX; Hiroji Iwata, PhD, MD, Aichi Cancer Center Hospital, Nagoya, Japan; Kenji Tamura, MD, PhD, National Cancer Center Hospital, Tokyo, Japan; Junji Tsurutani, MD, PhD, Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan and Kindai University Faculty of Medicine, Osaka, Japan; Alvaro Moreno-Aspitia, MD, Mayo Clinic, Jacksonville, FL; Toshihiko Doi, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan; Yasuaki Sagara, MD, Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan; Charles Redfern, MD, Sharp HealthCare, San Diego, CA; Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute, Boston, MA; Caleb Lee, MD, PhD, Daiichi Sankyo, Basking Ridge, NJ; Yoshihiko Fujisaki, MS and Masahiro Sugihara, PhD, Daiichi Sankyo, Tokyo, Japan; Lin Zhang, MD, PhD and Javad Shahidi, MD, Daiichi Sankyo, Basking Ridge, NJ; and Shunji Takahashi MD, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.01212DOI Listing
October 2020

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(27):2804-2807. Epub 2018 Jun 25.

Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Sharon H. Giordano, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Ian E. Krop, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2713DOI Listing
September 2018

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(26):2736-2740. Epub 2018 Jun 25.

Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Ian E. Krop, Nancy U. Lin, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jennifer Levinson, Ponte Vedra Beach; Naren Ramakrishna, Orlando Health University of Florida Health Cancer Center, Orlando, FL; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2697DOI Listing
September 2018

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2018 02 3;36(6):543-553. Epub 2018 Jan 3.

Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus, OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E. Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin, Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston; Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed, Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of Technology; and J. Christopher Love, Massachusetts Institute of Technology, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815405PMC
February 2018

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.

J Clin Oncol 2016 07 21;34(19):2303-11. Epub 2016 Mar 21.

N. Lynn Henry, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Vandana G. Abramson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Kimberly H. Allison, Stanford University Medical Center, Stanford; Diana T. Chingos, University of Southern California/Young Survival Coalition, Los Angeles; Arti Hurria, City of Hope, Duarte, CA; Carey K. Anders, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Thomas H. Openshaw, Eastern Maine Medical Center Cancer Care, Brewer, ME; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.8609DOI Listing
July 2016

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Cancer Cell 2016 Mar;29(3):255-269

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.02.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794996PMC
March 2016

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

J Clin Oncol 2016 Mar 1;34(9):945-52. Epub 2016 Feb 1.

Rachel A. Freedman, Rebecca S. Gelman, Christina Herold, Nicole Ryabin, Sarah Farooq, Elizabeth Lawler, Ian E. Krop, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute; Beverly Moy, Massachusetts General Hospital; Alarice Lowe and Nathalie Y.R. Agar, Brigham and Women's Hospital, Boston, MA; Jeffrey S. Wefel, Kenneth R. Hess, and Nuhad Ibrahim, The University of Texas MD Anderson Cancer Center; Polly A. Niravath and Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; Michelle E. Melisko, University of California, San Francisco, San Francisco, CA; Roisin M. Connolly and Antonio C. Wolff, Johns Hopkins University, Baltimore, MD; Catherine H. Van Poznak, University of Michigan, Ann Arbor, MI; Shannon L. Puhalla, University of Pittsburgh Cancer Institute and Magee-Women's Hospital, Pittsburgh, PA; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; and Minetta C. Liu, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/01/28/JCO.2015.63
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.63.0343
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.63.0343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070554PMC
March 2016

Lessons from breast cancer trials of HER2-kinase inhibitors.

Authors:
Ian E Krop

Lancet Oncol 2016 Mar 26;17(3):267-268. Epub 2016 Jan 26.

Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)00004-8DOI Listing
March 2016

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

J Clin Oncol 2016 Feb 2;34(6):542-9. Epub 2015 Nov 2.

Lisa A. Carey, David W. Ollila, Carey K. Anders, Katherine A. Hoadley, Michael Iglesia, and Charles M. Perou, University of North Carolina Chapel Hill, Chapel Hill; Constance T. Cirrincione and Brandelyn N. Pitcher, Alliance Statistics and Data Center, Duke University, Durham, NC; Donald A. Berry, Alliance Statistics and Data Center, MD Anderson, Houston, TX; William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute; Ian E. Krop and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Lyndsay N. Harris, University Hospitals of Cleveland, Cleveland, OH; Norah Lynn Henry, University of Michigan, Ann Arbor, MI; Douglas J. Weckstein, New Hampshire Hematology-Oncology, Hooksett, NH; Baljit Singh, New York University; Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; and Maggie Chon U. Cheang, Clinical Trials and Statistics Unit, Institute of Cancer Research, Belmont, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567PMC
February 2016

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.

Cancer J 2015 Sep-Oct;21(5):357-64

From the *Breast Cancer Research, Sarah Cannon Research Institute; and †Medical Oncology, Tennessee Oncology, PLLC, Nashville, TN; ‡Dana-Farber Cancer Institute, Boston, MA; §Smilow Cancer Center, Yale University, New Haven, CT; ∥AdvancedBC.org, New York, NY; ¶Genentech, Inc, South San Francisco, CA; and #Mayo Clinic, Jacksonville, FL.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/journalppo/2015/09000/Trastuzum
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000144DOI Listing
June 2016

The Evolving Landscape of HER2 Targeting in Breast Cancer.

JAMA Oncol 2015 Nov;1(8):1154-61

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.2286DOI Listing
November 2015

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

J Clin Oncol 2015 Aug 13;33(24):2623-31. Epub 2015 Jul 13.

Nancy U. Lin, Hao Guo, Nicole Ryabin, Julie S. Najita, William T. Barry, Ian E. Krop, Eric P. Winer, and Annick D. Van den Abbeele, Dana-Farber Cancer Institute; Andrea L. Richardson and Annick D. Van den Abbeele, Brigham and Women's Hospital, Boston, MA; Jeffrey T. Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Ingrid A. Mayer and Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN; Carla I. Falkson, University of Alabama, Birmingham, AL; Timothy J. Hobday, Mayo Clinic, Rochester, MN; E. Claire Dees, University of North Carolina, Chapel Hill, NC; Rita Nanda, University of Chicago, Chicago, IL; Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; and Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534525PMC
August 2015

Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer.

J Clin Oncol 2015 Apr 23;33(12):1407-9. Epub 2015 Mar 23.

Dana-Farber Cancer Institute, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0742DOI Listing
April 2015

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.

J Clin Oncol 2015 Apr 23;33(10):1136-42. Epub 2015 Feb 23.

Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA; Thomas M. Suter, Bern University Hospital, Bern, Switzerland; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York; Marc L. Citron, Hofstra North Shore-Long Island Jewish School of Medicine, New Hyde Park, NY; Luc Dirix, Sint-Augustinus Hospital, Antwerp, Belgium; Gilles Romieu, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier; Mario Campone, Institut de Cancérologie de l'Ouest/René Gauducheau, Nantes Saint-Herblain, France; Claudio Zamagni, Policlinico Sant'Orsola-Malpighi Hospital, Bologna; Luca Gianni, San Raffaele Hospital, Milan, Italy; and Na Xu and Melanie Smitt, Genentech, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.7782DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657012PMC
April 2015

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

N Engl J Med 2015 Jan;372(2):134-41

From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B., E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.) - both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medical Oncology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park (I.S.) - all in New York; Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville (D.A.Y.); Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham (P.K.M.), and Department of Medical Oncology, University of North Carolina, Chapel Hill (L.A.C.) - both in North Carolina; Cardinal Bernardin Cancer Center, Department of Medicine, Division of Hematology-Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of California, San Francisco, San Francisco (H.S.R.); Department of Medical Oncology, Washington University in St. Louis, St. Louis (M.E.); and Johns Hopkins Kimmel Cancer Center, Department of Oncology, Baltimore (A.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313867PMC
January 2015

Seeds and soil: unraveling the role of local tumor stroma in distant metastasis.

J Natl Cancer Inst 2014 Aug 31;106(8). Epub 2014 Jul 31.

Steele Laboratory for Tumor Biology, Department of Radiation Oncology (DGD, RKJ), and Department of Medicine (SJI), Massachusetts General Hospital and Harvard Medical School, Boston, MA; PAREXEL International, Waltham, MA (MA); Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (IEK).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/106/8/dju187.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/dju187
Publisher Site
http://dx.doi.org/10.1093/jnci/dju187DOI Listing
August 2014

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.

J Clin Oncol 2014 Sep 14;32(25):2750-7. Epub 2014 Jul 14.

Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.4999DOI Listing
September 2014

New research on the treatment of small HER2-positive breast cancers.

Authors:
Ian E Krop

Clin Adv Hematol Oncol 2014 Feb;12(2):124-7

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
February 2014

Trastuzumab: qui bono?

J Natl Cancer Inst 2013 Dec 21;105(23):1772-5. Epub 2013 Nov 21.

Affiliation of authors: Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt336DOI Listing
December 2013

Targeted therapies: HER2-positive breast cancer-sifting through many good options.

Authors:
Ian E Krop

Nat Rev Clin Oncol 2013 Jun 30;10(6):312-3. Epub 2013 Apr 30.

Dana-Farber Cancer Institute, Harvard University School of Medicine, Breast Oncology Center, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2013.72DOI Listing
June 2013

Prevalence of germline TP53 mutations in HER2+ breast cancer patients.

Breast Cancer Res Treat 2013 May 12;139(1):193-8. Epub 2013 Apr 12.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-012-2375-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280061PMC
May 2013

Author's reply: Use of discard pleural fluid in molecular research.

Nat Rev Clin Oncol 2012 Jan;9(1)

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University College of Medicine, 300 West 10 Avenue, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.114-c2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821068PMC
January 2012

The ethical use of mandatory research biopsies.

Nat Rev Clin Oncol 2011 08 2;8(10):620-5. Epub 2011 Aug 2.

Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2011.114
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2011.114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632075PMC
August 2011

A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases.

Clin Breast Cancer 2011 Dec 22;11(6):376-83. Epub 2011 Jun 22.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2011.03.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773692PMC
December 2011

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Clin Cancer Res 2010 Jul;16(14):3526-32

Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1834DOI Listing
July 2010

Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.

Cancer Res 2010 Mar 2;70(6):2256-63. Epub 2010 Mar 2.

Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute and Harvard Medical School, University of Massachusetts, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-4032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310185PMC
March 2010

Mechanisms of trastuzumab resistance in breast cancer.

Anticancer Agents Med Chem 2009 Mar;9(3):348-55

Dana Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871520610909030348DOI Listing
March 2009

Ten years of HER2-directed therapy: still questions after all these years.

Breast Cancer Res Treat 2009 Jan 8;113(2):207-9. Epub 2008 May 8.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10549-008-0041
Web Search
http://link.springer.com/10.1007/s10549-008-0041-2
Publisher Site
http://dx.doi.org/10.1007/s10549-008-0041-2DOI Listing
January 2009

Chemokine signaling in gliomas: prognostic factor, therapeutic target or both?

Authors:
Ian E Krop

Cancer Biol Ther 2006 Aug 5;5(8):1039-41. Epub 2006 Aug 5.

Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.5.8.3021DOI Listing
August 2006

Ovarian suppression for breast cancer: an effective treatment in search of a home.

J Clin Oncol 2005 Sep 8;23(25):5869-72. Epub 2005 Aug 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.06.002DOI Listing
September 2005